Clinical trials
Hematologic Diseases trials in the United States with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
38 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 6 |
| 2001 | 3 |
| 2003 | 1 |
| 2005 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 5 |
| 2020 | 3 |
| 2022 | 1 |
| 2023 | 2 |
| 2025 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 24 |
| Recruiting | 5 |
| Terminated | 5 |
| Unknown status | 3 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fairview University Medical Center | 6 |
| Massachusetts General Hospital | 3 |
| Duke University | 2 |
| Emory University | 2 |
| Milton S. Hershey Medical Center | 2 |
| Abbott Medical Devices | 1 |
| Alice Bertaina | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Boston Children's Hospital | 1 |
| Brigham and Women's Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hematologic Diseases | 38 |
| Rare Diseases | 10 |
| Genetic Diseases, Inborn | 7 |
| Anemia, Sickle Cell | 6 |
| Graft vs Host Disease | 6 |
| Hematologic Neoplasms | 6 |
| Neoplasms | 5 |
| Anemia, Aplastic | 4 |
| Leukemia | 4 |
| Communicable Diseases | 3 |
Trials
Showing 1 to 25 of 38. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.